For the treatment of CF, four targeted drugs have been registered by FDA and EMA, consisting of a potentiator ivacaftor and correctors, namely, lumacaftor, tezacaftor, and elexacaftor, in different combinations that eliminate specific defects of the CFTR protein [10]. Here, CFTR is linked to cystic fibrosis.